Anti-Coagulants - Bangladesh

Bangladesh

In Bangladesh, the revenue in the Anti-Coagulants market is projected to reach US$22.18m in 2024.
Looking ahead, it is expected that the revenue will show an annual growth rate (CAGR 2024-2029) of 9.05%, leading to a market volume of US$34.20m by 2029.
When comparing globally, United States is anticipated to generate the highest revenue in this market, amounting to US$16,740.00m in 2024.
Bangladesh is experiencing a growing demand for anti-coagulants due to an increasing elderly population and rising prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Bangladesh has been steadily growing in recent years, driven by various factors such as an aging population and increasing prevalence of cardiovascular diseases.

Customer preferences: In Bangladesh, there is a growing demand for anti-coagulants due to the rising incidence of heart diseases and stroke. Patients are also becoming more aware of the benefits of early detection and treatment, leading to an increase in demand for anti-coagulants.

Trends in the market: One of the major trends in the Anti-Coagulants market in Bangladesh is the shift towards newer oral anticoagulants. These drugs are more effective and have fewer side effects compared to traditional blood thinners such as warfarin. Another trend is the increasing use of anti-coagulants for indications such as deep vein thrombosis and pulmonary embolism.

Local special circumstances: Bangladesh has a large population of elderly people who are at a higher risk of developing cardiovascular diseases. In addition, the country has a high prevalence of risk factors such as obesity, diabetes, and hypertension, which contribute to the growing demand for anti-coagulants. However, there are also challenges such as limited access to healthcare and low awareness about the importance of preventive measures.

Underlying macroeconomic factors: The healthcare sector in Bangladesh has been growing rapidly in recent years, with increasing investment in infrastructure and technology. This has led to improved access to healthcare services and a greater demand for pharmaceutical products. In addition, the government has implemented various initiatives to improve healthcare outcomes, such as the National Health Policy and the Health, Nutrition and Population Sector Program. These factors are expected to drive the growth of the Anti-Coagulants market in Bangladesh in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.